Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACHILLES THERAPEUTICS PLC

(ACHL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
4.94(c) 5.1(c) 4.91(c) 4.89(c) 4.511 Last
81 618 121 109 67 238 120 046 102 452 Volume
+2.07% +3.24% -3.73% -0.41% -7.75% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -61,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,87x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -102 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,09x
Yield 2022 -
Capitalization 199 M 199 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 156
Free-Float 98,1%
More Financials
Company
Achilles Therapeutics plc is a clinical stage immuno-oncology biopharmaceutical company that is engaged in developing precision T cell therapies to treat multiple types of solid tumors. The Company has developed a bioinformatic platform called PELEUS, which is used to identify clonal neoantigens in patients. The Company's manufacturing process, VELOS, uses the patientÔÇÖs T cells and blood-derived dendritic cells to... 
More about the company
All news about ACHILLES THERAPEUTICS PLC
11/12European ADRs Move Lower in Friday Trading
MT
11/12Achilles Post-SITC Review and Corporate Update
PU
11/12SITC 2021 POSTER 193 : The Achilles VELOSTM Process 2 boosts the dose of highly functional..
PU
11/12Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer Annual M..
CI
11/09Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business ..
PU
11/09Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business ..
GL
11/09Achilles Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Month..
CI
11/09SITC 2021 POSTER 543 : Sensitive quantification and tracking of the active components of c..
PU
10/28European ADRs Gain Thursday as Anheuser-Busch InBev Jumps 10%
MT
10/27European ADRs 0.3% Lower Wednesday as Equinor, Rio Tinto Retreat
MT
10/25European ADRs Move Lower in Monday Trading
MT
10/22ACHILLES THERAPEUTICS : Presents Research Data for Velos Cancer Therapy Manufacturing Proc..
MT
10/22ESGCT 2021 OR54 : Multicentre, prospective research protocol for development of a clonal n..
PU
10/22ACHILLES THERAPEUTICS : Presents Data at the 2021 European Society for Gene and Cell Thera..
AQ
10/22Achilles Therapeutics Presents Data At the 2021 European Society for Gene and Cell Ther..
CI
More news
News in other languages on ACHILLES THERAPEUTICS PLC
11/12Les ADR européens en baisse vendredi
10/28Les ADR européens progressent jeudi avec un bond de 10 % d'Anheuser-Busch InBev.
10/27Les ADR européens en baisse de 0,3 % mercredi, en raison du recul d'Equinor et de Rio T..
10/25Les ADR européens en baisse lundi
10/22Achilles Therapeutics présente des données de recherche sur le processus de fabrication..
More news
Analyst Recommendations on ACHILLES THERAPEUTICS PLC
More recommendations
Chart ACHILLES THERAPEUTICS PLC
Duration : Period :
Achilles Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACHILLES THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 4,89 $
Average target price 23,34 $
Spread / Average Target 377%
EPS Revisions
Managers and Directors
Iraj Ali Chief Executive Officer & Director
Robert Coutts Chief Financial Officer
Edwin Moses Chairman
Karl Peggs Chief Medical Officer
Sergio Quezada Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ACHILLES THERAPEUTICS PLC0.00%199
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-40.67%24 745